- Daimler Trucks hands over first all-electric FUSO eCanter trucks to customers
- Daimler launches new DENZA electric vehicle for the Chinese market
- Pride Tour 2018: Daimler supports tolerance and diversity worldwide
- Cortec® Introduces EcoShield® Super Barrier Paper and Linerboard
- Amey and Sersa, as part of the S&C North Alliance, win Infrastructure Achievement Award at National Rail Awards
- Industry calls for urgent clarity on EU workers as survey shows recruitment crunch looming
- Rimac opens 100 new jobs
- Covestro expands global capacity for polyurethane dispersions
Chemicals and Pharmaceuticals
Novartis has announced long-term study results supporting the positive safety and efficacy of Revolade (eltrombopag) in adults with chronic/persistent (enrolling patients that were 6 or more months from diagnosis) immune (idiopathic) thrombocytopenia (ITP) were published online in Blood.
Sanofi and Regeneron Pharmaceuticals, Inc. has announced positive results from a Phase 2 investigational study of dupilumab in adults with active moderate-to-severe eosinophilic esophagitis.
AkzoNobel's Specialty Chemicals business has entered the design phase of a further capacity expansion in Germany to produce chloromethanes - a key ingredient in the manufacture of pharmaceuticals and electronics.
Considering the planned acquisition of Monsanto, Bayer has signed an agreement to sell selected Crop Science businesses to BASF for €5.9 billion. The assets to be sold generated net sales of approximately €1.3 billion in 2016.
Janssen Biotech, Inc. has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Apalutamide, an investigational, next-generation oral androgen receptor (AR) inhibitor for men with non-metastatic castration-resistant prostate cancer (CRPC).
Fluor Corporation (NYSE: FLR) announced today that it was selected by LyondellBasell (NYSE: LYB) to perform the engineering and procurement for its propylene oxide (PO) and tertiary butyl alcohol (TBA) project located at its Channelview and Bayport complexes outside of Houston.
Novartis has joined forces with researchers from the University of California, Berkeley, to develop new technologies for the discovery of next-generation therapeutics, pursuing the vast number of disease targets in cancer and other illnesses that have eluded traditional small-molecule compounds and are considered “undruggable.”
Janssen-Cilag International NV (Janssen) today announced that the European Commission has approved the use of Symtuza®, a once-daily darunavir-based single-tablet regimen (STR), for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents aged 12 years and older with a body weight of at least 40 kg.